Location History:
- Göttingen, DE (2002)
- Gottingen, DE (2002 - 2010)
Company Filing History:
1 out of 4 
2 out of 832,761 Years Active: 2002-2010
Title: Georg-Ferdinand Schlingensiepen: Innovator in Antisense-Oligonucleotide Research
Introduction
Georg-Ferdinand Schlingensiepen is a notable inventor based in Göttingen, Germany. He has contributed significantly to the field of molecular biology with a focus on antisense-oligonucleotides. With a portfolio of three patents, Schlingensiepen's innovations hold promise for advancing the treatment of various medical conditions.
Latest Patents
Schlingensiepen's latest patents revolve around the use of antisense-oligonucleotides targeting the immuno-suppressive effects of transforming growth factor-beta (TGF-β). His patents detail antisense-oligonucleotides or effective derivatives that hybridize with specific gene coding areas for TGF-β, which are outlined in sequence listings. These patents include comprehensive sequences identified as SEQ ID NO. 1-56, 137, and SEQ ID NO. 57-136, each exhibiting either a DNA- or RNA-type structure.
Career Highlights
Throughout his career, Schlingensiepen has been affiliated with prominent organizations such as Biognostik Gesellschaft für Biomolekulare Diagnostik mbH. His work has contributed to significant advancements in biomolecular diagnostics. His expertise in antisense technology has not only garnered patents but has also positioned him as a key figure in his field.
Collaborations
In his professional journey, Georg-Ferdinand Schlingensiepen has collaborated with respected coworkers, including Wolfgang Brysch and Karl-Hermann Schlingensiepen. These collaborations have further enriched his research, allowing for the development of innovative solutions in the biomedical arena.
Conclusion
Georg-Ferdinand Schlingensiepen stands out as an innovator in the realm of antisense-oligonucleotide research. His patents signify important strides in addressing immuno-suppressive conditions through targeted molecular therapies. As the landscape of biomedical research evolves, Schlingensiepen's contributions are likely to play a vital role in future innovations.